½ÃÀ庸°í¼­
»óǰÄÚµå
1759485

¼¼°èÀÇ ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ ½ÃÀå : ¼øµµ, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, À¯Åë°æ·Î, Áö¿ªº°(-2032³â)

Global Artesunate Injection Market Research Report Information by Purity, by Application, by End User, by Distribution Channel, by Region Industry Forecast till 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Market Research Future | ÆäÀÌÁö Á¤º¸: ¿µ¹® 107 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ ½ÃÀå ±Ô¸ð´Â 2023³â ¾à 8,500¸¸ ´Þ·¯¿¡¼­ 2024-2032³âÀÇ ¿¹Ãø ±â°£ Áß 0.9%ÀÇ CAGR·Î ¿Ï¸¸ÇÏ°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ¸»¶ó¸®¾Æ ¹ßº´·ü Áõ°¡, Áï°¢ÀûÀÎ ÁÖ»ç ¿ä¹ý¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, Á¦Á¶ ¹× À¯Åë ½Ã½ºÅÛÀÇ ¹ßÀü µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àü ¼¼°èÀûÀÎ ÀÎ½Ä °³¼± ¹× Á¶±â Áø´ÜÀ» À§ÇÑ È«º¸ Ȱµ¿µµ Ä¡·áÀ² Çâ»ó¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

±×·¯³ª ¸î °¡Áö Á¦¾àÀÌ ½ÃÀåÀÇ ÀáÀç·ÂÀ» °¡·Î¸·°í ÀÖ½À´Ï´Ù. ³ôÀº Á¦Á¶ ¹× Ä¡·á ºñ¿ë, Áö¿ª¿¡ µû¶ó °ø±ÞÀÌ ºÒ¾ÈÁ¤ÇÑ Á¡, ¾ö°ÝÇÑ ±ÔÁ¦ ½ÂÀÎ ÀýÂ÷ µîÀÌ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁöÀûÀç»ê±Ç°ú °ü·ÃµÈ º¹ÀâÇÑ ¹®Á¦¿Í ´Ù¸¥ Ç׸»¶ó¸®¾ÆÁ¦¿ÍÀÇ °æÀïµµ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ¾Ð¹ÚÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ Á¦¾à¿¡µµ ºÒ±¸ÇÏ°í ¼ºÀåÀÇ ±âȸ´Â Á¸ÀçÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ¿ø°ÝÀÇ·á Ç÷§ÆûÀÇ º¸±ÞÀ¸·Î ¸»¶ó¸®¾Æ°¡ À¯ÇàÇÏ´Â Áö¿ªÀÇ ¿ø°ÝÁö¿¡¼­µµ Áø´Ü°ú Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹Î°ü Çù·Â °­È­·Î ¸»¶ó¸®¾Æ °ü·Ã ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÀÚ±Ý Áö¿øÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áö¿ªº° Á¦Á¶ °ÅÁ¡ ±¸ÃàÀÌ °ø±Þ¸Á ¾ÈÁ¤È­¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÀÇ·á ÀÎÇÁ¶ó Àü¹ÝÀÇ ¹ßÀüÀÌ ¾ËÅ×½º³×ÀÌÆ® ÁÖ»çÁ¦¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»óÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Áö¿ªº° Àü¸Á

ºÏ¹Ì¿¡¼­´Â Àü ¼¼°è¿¡¼­ °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¾ËÅ×½º³×ÀÌÆ® ÁÖ»çÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÁÖ·Î ¸»¶ó¸®¾Æ°¡ À¯ÇàÇÏ´Â Áö¿ªÀ¸·ÎÀÇ ¿©ÇàÀÚ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ij³ª´Ù¿Í ¹Ì±¹¿¡¼­´Â ¸»¶ó¸®¾ÆÀÇ ÅäÂø °¨¿°Àº ¾øÁö¸¸, ÇØ¿Ü¿¡¼­ À¯ÀԵǴ »ç·Ê°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÁßÁõÈ­¸¦ ¿¹¹æÇϱâ À§ÇØ ½Å¼ÓÇϰí È¿°úÀûÀÎ Ä¡·áÁ¦ÀÎ ¾ËÅ×½º³×ÀÌÆ®¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

À¯·´¿¡¼­´Â À¯·´ÀǾàǰû(EMA)ÀÌ ¾ËÅ×½º³×ÀÌÆ®°¡ ÁßÁõ ¸»¶ó¸®¾Æ¿¡ ´ëÇÑ ¸Å¿ì È¿°úÀûÀÎ Ä¡·áÁ¦·Î ÀÎÁ¤Çϰí ÀÖÀ¸¸ç, ¸¹Àº ±¹°¡¿¡¼­ ±¹°¡ Ä¡·á °¡À̵å¶óÀο¡ Æ÷ÇÔ½Ã۰í ÀÖ½À´Ï´Ù. ±×·¯³ª ±ÔÁ¦ º¹À⼺ ¹× ºñ¿ë °ü·Ã ¹®Á¦°¡ ³²¾Æ ÀÖÀ¸¸ç, Áö¿ª Àüü¿¡ ±¤¹üÀ§ÇÏ°Ô µµÀԵǴ µ¥¿¡´Â ÇѰ谡 ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â ¼¼°èº¸°Ç±â±¸(WHO)°¡ ÁßÁõ ¸»¶ó¸®¾ÆÀÇ 1Â÷ ¼±ÅþàÀ¸·Î ¾Æ¸£Å×½º³×Æ®¸¦ ±Ç°íÇÔ¿¡ µû¶ó ±× µµÀÔÀÌ È®»êµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ±Ç°í¿¡ µû¶ó ¸»¶ó¸®¾Æ°¡ À¯ÇàÇÏ´Â ±¹°¡¿¡¼­´Â °ø½ÄÀûÀÎ ÀÇ·á ÇÁ·ÎÅäÄÝ¿¡ Á¤½ÄÀ¸·Î ÀÓº£µðµåµÇ¾î ½ÇÁ¦ ÀÓ»ó ÇöÀå¿¡¼­ÀÇ »ç¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

³²¹Ì¿¡¼­´Â Æä·ç, ºê¶óÁú, ÄÝ·Òºñ¾Æ µî ¾Æ¸¶Á¸ À¯¿ª ±¹°¡µéÀÇ ¸»¶ó¸®¾Æ °¨¿°·üÀÌ ¿©ÀüÈ÷ ³ôÀ¸¸ç, ƯÈ÷ ÁßÁõ ȯÀÚ¿¡¼­ ¾ËÅ×½º³×ÀÌÆ®°¡ °¢±¹ÀÇ ¸»¶ó¸®¾Æ ÅðÄ¡ ÇÁ·Î±×·¥¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

Áß¾Ó¾ÆÇÁ¸®Ä« ±¹°¡, ƯÈ÷ Äá°í¹ÎÁÖ°øÈ­±¹ µî¿¡¼­´Â ¸Å¿ì ³ôÀº ¸»¶ó¸®¾Æ ¹ßº´·ü¿¡ Á÷¸éÇØ ÀÖÀ¸¸ç, ¾ËÅ×½º³×ÀÌÆ®´Â ÃÖÀü¼± Ä¡·áÁ¦·Î¼­ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀåÀÇ Á¤ÀÇ¿Í °³¿ä, ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ °¢Á¾ ¿µÇâ¿äÀÎÀÇ ºÐ¼®, ½ÃÀå ±Ô¸ð ÃßÀÌ¡¤¿¹Ãø, °¢Á¾ ±¸ºÐ¡¤Áö¿ª/ÁÖ¿ä ±¹°¡º° ³»¿ª, °æÀï ȯ°æ, ÁÖ¿ä ±â¾÷ÀÇ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ÃËÁø¿äÀÎ
    • ¸»¶ó¸®¾ÆÀÇ À¯º´·ü Áõ°¡
    • Áֻ翡 ÀÇÇÑ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • Á¦Á¶¡¤À¯Åë ±â¼úÀÇ Áøº¸
    • °è¹ß Ȱµ¿°ú ±³À° ¼öÁØÀÇ Çâ»ó
  • ¾ïÁ¦¿äÀÎ
    • ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ÀÇ °íºñ¿ë
    • ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ÀÇ Á¦ÇÑµÈ °¡¿ë¼º
    • ±ÔÁ¦»ó °úÁ¦ ¹× ½ÂÀÎ ÇÁ·Î¼¼½ºÀÇ Àå±âÈ­
    • ÁöÀûÀç»ê±Ç ¹× ƯÇã¿¡ °üÇÑ ¹®Á¦
    • ±âŸ Ç׸»¶ó¸®¾Æ Ä¡·áÁ¦¿ÍÀÇ °æÀï
  • ±âȸ
    • ¿ø°Ý Áø·á ¼­ºñ½ºÀÇ È®´ë¿¡ ÀÇÇÑ ¿ø°ÝÁö¿¡¼­ Áø´Ü¡¤Ä¡·áÀÇ °¡´É¼º Çâ»ó
    • ¸»¶ó¸®¾Æ ¿¬±¸¿¡ ´ëÇÑ ¹Î°ü Á¦ÈÞ¿¡ ÀÇÇÑ ÀÚ±ÝÁ¶´ÞÀÇ Áõ°¡
    • Ä¡·á È¿°ú¸¦ ³ôÀ̱â À§ÇÑ º´¿ë¿ä¹ýÀÇ °³¹ß
    • °ø±Þ¸ÁÀÇ °­È­¸¦ ¸ñÀûÀ¸·Î ÇÑ Áö¿ª Á¦Á¶ ±â¹ÝÀÇ ºÎ»ó
    • ÇコÄÉ¾î ¾÷°è Àüü¿¡ ´ëÇÑ ¿µÇâ
    • ¼¼°èÀÇ ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ
    • ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ ½ÃÀåÀÇ °ø±Þ¸Á¿¡ ´ëÇÑ ¿µÇâ
    • ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ö¿ä¿¡ ´ëÇÑ ¿µÇâ
    • ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ ½ÃÀåÀÇ °¡°Ý¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ½ÃÀå ¿äÀÎ ºÐ¼®

  • °ø±Þ¸Á ºÐ¼®
  • Porter's Five Forces ¸ðµ¨

Á¦6Àå ¼¼°èÀÇ ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ ½ÃÀå : ¼øµµº°

  • ¾Æ¸£Å×¼ö³×ÀÌÆ® 0.99
  • ¾Æ¸£Å×¼ö³×ÀÌÆ® 0.98

Á¦7Àå ¼¼°èÀÇ ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ ½ÃÀå : ¿ëµµº°

  • ¸»¶ó¸®¾Æ
  • ÁßÁõ ¸»¶ó¸®¾Æ
  • ³ú¸»¶ó¸®¾Æ
  • ÇÕº´Áõ ¾ø´Â ¸»¶ó¸®¾Æ

Á¦8Àå ¼¼°èÀÇ ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Ŭ¸®´Ð
  • ¾à±¹
  • Á¤ºÎ±â°ü
  • ºñÁ¤ºÎ Á¶Á÷

Á¦9Àå ¼¼°èÀÇ ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ ½ÃÀå : À¯Åë ä³Îº°

  • Á÷Á¢ ÆÇ¸Å
  • ÆÇ¸Å¾÷ü ¹× µµ¸Å¾÷ü
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ÆÇ¸Å

Á¦10Àå ¼¼°èÀÇ ¾Æ¸£Å×¼ö³×ÀÌÆ® ÁÖ»çÁ¦ ½ÃÀå : Áö¿ªº°

  • °³¿ä
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®
  • °æÀï ´ë½Ãº¸µå
  • ÁÖ¿ä °³¹ß¡¤¼ºÀå Àü·«

Á¦12Àå ±â¾÷ °³¿ä

  • AMIVAS
  • ADVACARE PHARMA
  • ZYDUS CADILA
  • INTAS PHARMACEUTICAL
  • SYSTACARE REMEDIES
  • LEXICARE PHARMA
  • CIPLA
  • GUILIN PHARMA
  • IPCA LABORATORIES
  • WATRAN PHARMACEUTICALS PVT. LTD
KSA 25.07.08

Global Artesunate Injection Market Research Report Information by Purity (Artesunate 0.99, Artesunate 0.98), by Application (Malaria, Severe Malaria, Cerebral Malaria, Uncomplicated Malaria, Other Applications), by End User (Hospitals, Clinics, Pharmacies, Government Institutions, Non-Governmental Organizations), by Distribution Channel (Direct Sales, Distributors and Wholesalers, Retail Pharmacies, and Online Sales), by Region (North America, Europe, APAC, South America, MEA) Industry Forecast till 2032

Market Analysis

In 2023, the global artesunate injection market reached a valuation of approximately USD 85 million. From 2024 to 2032, the market is anticipated to grow at a modest compound annual growth rate (CAGR) of 0.9%. Key growth factors include the increasing burden of malaria, the rising preference for injectable therapies that offer rapid action, and advancements in manufacturing and distribution systems. In addition, improved awareness and early diagnosis due to global education initiatives have positively influenced treatment rates.

However, several limitations hinder the market's potential. High production and treatment costs, inconsistent availability in various regions, and stringent regulatory approval processes create roadblocks. Complex intellectual property issues and competition from alternative antimalarial drugs also add pressure to market growth.

Despite these restraints, opportunities exist. The rise of telehealth platforms is helping expand access to diagnosis and treatment in remote, malaria-affected regions. Furthermore, increased collaboration between public and private sectors is resulting in greater funding for malaria-related healthcare solutions. The development of regional manufacturing centers is improving supply chain stability, and general progress in healthcare infrastructure is facilitating better access to artesunate injections. Together, these trends are shaping market dynamics and influencing future pricing, accessibility, and overall demand for artesunate therapies.

Industry Segmentation

Depending on the purity type, the global artesunate injection market is divided into Artesunate 0.99 and Artesunate 0.98.

The global artesunate injection market is divided into end user industry, such as hospitals, clinics, pharmacies, government institutions, non-governmental organizations.

The application type of the global market comprises malaria, severe malaria, cerebral malaria, uncomplicated malaria, other applications.

Based on the distribution channel, the global market has been categorized into direct sales, distributors and wholesalers, retail pharmacies, and online sales.

In terms of regions, the global market comprises, Middle East & Africa, Europe, North America, South America, and Asia Pacific.

Regional Perspectives

In North America, increasing global health awareness has contributed to rising demand for artesunate injections, primarily due to the growing number of travelers visiting malaria-endemic countries. Although malaria is not endemic in Canada or the United States, the region has witnessed a rise in imported cases, necessitating access to rapid and effective treatments like artesunate to prevent severe complications.

In Europe, artesunate has gained recognition from the European Medicines Agency (EMA) as a highly effective treatment for severe malaria. Consequently, many countries have incorporated it into their national treatment guidelines. However, regulatory complexities and cost-related challenges still limit its broader use across the continent.

The Asia-Pacific region has seen expanded adoption of artesunate, largely driven by the World Health Organization's (WHO) recommendation endorsing it as the first-line treatment for severe malaria. This has led to its inclusion in official healthcare protocols throughout malaria-prone nations in the region.

In South America, nations within the Amazon Basin, including Peru, Brazil, and Colombia, continue to experience high rates of malaria transmission. Artesunate plays a crucial role in national malaria response programs, especially for severe infections.

Central African countries like the Democratic Republic of the Congo (DRC) face a heavy malaria burden, where artesunate remains an essential component of frontline treatment.

Major Competitors

Cipla, Guilin Pharma, IPCA Laboratories, AMIVAS, Advacare Pharma, Zydus Cadila, Intas Pharmaceutical, Systacare Remedies, Lexicare Pharma, Watran Pharmaceuticals Pvt. Ltd. are the leading companies in the Global Artesunate Injection Market Research.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 DATA MINING PROCESS
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 SECONDARY RESEARCH DATA FLOW:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 PRIMARY RESEARCH DATA FLOW:
    • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
    • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
  • 3.6 APPROACHES FOR MARKET END USER ESTIMATION:
    • 3.6.1 REVENUE ANALYSIS APPROACH
    • 3.6.2 DATA FORECASTING
    • 3.6.3 DATA FORECASTING TECHNIQUE
  • 3.7 DATA MODELING
    • 3.7.1 MICROECONOMIC FACTOR ANALYSIS:
    • 3.7.2 DATA MODELING:
  • 3.8 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 INCREASING PREVALENCE OF MALARIA
    • 4.2.2 GROWING DEMAND FOR INJECTABLE TREATMENTS
    • 4.2.3 ADVANCEMENTS IN MANUFACTURING AND DISTRIBUTION
    • 4.2.4 GROWING AWARENESS AND EDUCATION
  • 4.3 RESTRAINTS
    • 4.3.1 HIGH COST OF ARTESUNATE INJECTIONS
    • 4.3.2 LIMITED AVAILABILITY IN CERTAIN REGIONS
    • 4.3.3 REGULATORY CHALLENGES AND LENGTHY APPROVAL PROCESSES
    • 4.3.4 INTELLECTUAL PROPERTY AND PATENT ISSUES
    • 4.3.5 COMPETING ANTIMALARIAL THERAPIES
  • 4.4 OPPORTUNITY
    • 4.4.1 EXPANSION OF TELEHEALTH SERVICES FOR REMOTE DIAGNOSIS AND TREATMENT
    • 4.4.2 INCREASED PUBLIC-PRIVATE PARTNERSHIPS FOR FUNDING MALARIA RESEARCH
    • 4.4.3 DEVELOPMENT OF COMBINATION THERAPIES TO ENHANCE TREATMENT EFFICACY
    • 4.4.4 EMERGENCE OF REGIONAL MANUFACTURING HUBS TO BOOST SUPPLY CHAIN RESILIENCE
    • 4.4.5 IMPACT ON OVERALL HEALTHCARE SECTOR
    • 4.4.6 IMPACT ON GLOBAL ARTESUNATE INJECTION MARKET
    • 4.4.7 IMPACT ON THE SUPPLY CHAIN OF THE ARTESUNATE INJECTION MARKET
    • 4.4.8 IMPACT ON MARKET DEMAND OF ARTESUNATE INJECTION MARKET
    • 4.4.9 IMPACT ON PRICING OF ARTESUNATE INJECTION MARKET

5 MARKET FACTOR ANALYSIS

  • 5.1 SUPPLY CHAIN ANALYSIS
    • 5.1.1 RAW MATERIAL SUPPLIERS
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION AND LOGISTICS
    • 5.1.4 RETAIL AND CONSUMPTION
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 BARGAINING POWER OF SUPPLIERS
    • 5.2.2 BARGAINING POWER OF BUYERS
    • 5.2.3 THREAT OF NEW ENTRANTS
    • 5.2.4 THREAT OF SUBSTITUTES
    • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY

  • 6.1 INTRODUCTION
  • 6.2 ARTESUNATE 0.99
  • 6.3 ARTESUNATE 0.98

7 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • 7.1.1 MALARIA
    • 7.1.2 SEVERE MALARIA
    • 7.1.3 CEREBRAL MALARIA
    • 7.1.4 UNCOMPLICATED MALARIA

8 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER

  • 8.1 INTRODUCTION
    • 8.1.1 HOSPITALS
    • 8.1.2 CLINICS
    • 8.1.3 PHARMACIES
    • 8.1.4 GOVERNMENT INSTITUTIONS
    • 8.1.5 NON-GOVERNMENTAL ORGANIZATIONS

9 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL

  • 9.1 INTRODUCTION
    • 9.1.1 DIRECT SALES
    • 9.1.2 DISTRIBUTORS AND WHOLESALERS
    • 9.1.3 RETAIL PHARMACIES
    • 9.1.4 ONLINE SALES

10 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION

  • 10.1 OVERVIEW
  • 10.2 NORTH AMERICA
  • 10.3 EUROPE
  • 10.4 ASIA PACIFIC
  • 10.5 SOUTH AMERICA
  • 10.6 MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 MARKET SHARE ANALYSIS, 2023
  • 11.3 COMPETITOR DASHBOARD
  • 11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 11.4.1 LAUNCH DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 AMIVAS
    • 12.1.1 COMPANY OVERVIEW
    • 12.1.2 TYPES OFFERED
    • 12.1.3 SWOT ANALYSIS
    • 12.1.4 KEY STRATEGY
  • 12.2 ADVACARE PHARMA
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 TYPES OFFERED
    • 12.2.3 SWOT ANALYSIS
    • 12.2.4 KEY STRATEGY
  • 12.3 ZYDUS CADILA
    • 12.3.1 COMPANY OVERVIEW
    • 12.3.2 TYPES OFFERED
    • 12.3.3 SWOT ANALYSIS
    • 12.3.4 KEY STRATEGY
  • 12.4 INTAS PHARMACEUTICAL
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 TYPES OFFERED
    • 12.4.3 SWOT ANALYSIS
    • 12.4.4 KEY STRATEGY
  • 12.5 SYSTACARE REMEDIES
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 TYPES OFFERED
    • 12.5.3 SWOT ANALYSIS
    • 12.5.4 KEY STRATEGY
  • 12.6 LEXICARE PHARMA
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 TYPES OFFERED
    • 12.6.3 SWOT ANALYSIS
  • 12.7 CIPLA
    • 12.7.1 COMPANY OVERVIEW
    • 12.7.2 TYPES OFFERED
    • 12.7.3 SWOT ANALYSIS
    • 12.7.4 KEY STRATEGY
  • 12.8 GUILIN PHARMA
    • 12.8.1 COMPANY OVERVIEW
    • 12.8.2 TYPES OFFERED
    • 12.8.3 SWOT ANALYSIS
  • 12.9 IPCA LABORATORIES
    • 12.9.1 COMPANY OVERVIEW
    • 12.9.2 TYPES OFFERED
    • 12.9.3 SWOT ANALYSIS
  • 12.10 WATRAN PHARMACEUTICALS PVT. LTD
    • 12.10.1 COMPANY OVERVIEW
    • 12.10.2 TYPES OFFERED
    • 12.10.3 SWOT ANALYSIS
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦